1. Academic Validation
  2. T0901317 is a dual LXR/FXR agonist

T0901317 is a dual LXR/FXR agonist

  • Mol Genet Metab. 2004 Sep-Oct;83(1-2):184-7. doi: 10.1016/j.ymgme.2004.07.007.
Keith A Houck 1 Kristen M Borchert Christopher D Hepler Jeffrey S Thomas Kelli S Bramlett Laura F Michael Thomas P Burris
Affiliations

Affiliation

  • 1 RTP Laboratories, Eli Lilly & Company, Research Triangle Park, NC 27709, USA.
Abstract

We characterize the ability of the liver X receptor (LXRalpha [NR1H3] and LXRbeta [NR1H2]) agonist, T0901317, to activate the farnesoid X receptor (FXR [NR4H4]). Although T0901317 is a much more potent activator of LXR than FXR, this ligand actually activates FXR more potently than a natural bile acid FXR ligand, chenodeoxycholic acid. Thus, the FXR activity of T0901317 must be considered when utilizing this agonist as a pharmacological tool to investigate LXR function.

Figures
Products